| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Aim Immunotech Inc. (AIM) has 5 insiders with recent SEC Form 4 filings, including 10 buys and 0 sells. AIM is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 1.97M | $1.18M | - | |
| Dir | 521.7K | $311.5K | - | |
| COO | 401.8K | $239.9K | - | |
| CEO | 63.9K | $38.2K | - | |
| Dir | 28.4K | $17.0K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 2, 2017 | Strayer David R | Chief Science/ Medical Officer | Buy | 7,937 | $0.63 | $5,000.31 | +23.4% | |
| May 2, 2017 | Pascale Adam | CFO | Buy | 15,873 | $0.63 | $9,999.99 | +137.8% | |
| Apr 27, 2017 | Equels Thomas K. | CEO, President | Buy | 72,464 | $0.69 | $50,000.16 | +17.2% | |
| Apr 11, 2017 | Equels Thomas K. | CEO, President | Buy | 200,000 | $0.50 | $100,000.00 | +90.7% | |
| Feb 16, 2017 | Strayer David R | Chief Science/ Medical Officer | Buy | 9,892 | $0.46 | $4,550.32 | +41.3% | |
| Feb 16, 2017 | Springate Wayne S. | Sr VP Of Operations | Buy | 8,014 | $0.46 | $3,686.44 | +33.4% | |
| Feb 16, 2017 | Pascale Adam | CFO | Buy | 6,981 | $0.46 | $3,211.26 | +153.9% | |
| Dec 22, 2016 | Equels Thomas K. | CEO, President | Buy | 68,493 | $0.73 | $49,999.89 | +45.1% | |
| Nov 1, 2016 | Equels Thomas K. | CEO,President | Buy | 10,000 | $1.00 | $10,000.00 | +7.0% | |
| Aug 24, 2016 | Appelrouth Stewart | Director | Buy | 15,750 | $2.21 | $34,807.50 | New |